Vir Biotechnology Inc (VIR)

$5.50 -0.15 (-2.65%)
Market Cap 781.05M
Revenue (ttm) 74.21M
Net Income (ttm) -521.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -703.36%
Debt to Equity Ratio 0.00
Volume 1,059,300
Avg Vol 1,368,494
Day's Range N/A - N/A
Shares Out 138.24M
Stochastic %K 45%
Beta 1.22
Analysts Strong Sell
Price Target $17.62

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 906 4324
Website: www.vir.bio
Address:
1800 Owens Street, Suite 900, San Francisco, United States
BASEflyer
BASEflyer Jul. 11 at 2:56 PM
$VIR lol down almost 5% with 250k volume 🤣🤣🤣
0 · Reply
JarvisFlow
JarvisFlow Jul. 11 at 1:05 PM
Raymond James has updated their rating for Vir Biotechnology ( $VIR ) to Outperform with a price target of 12.
1 · Reply
Dunnieboy1
Dunnieboy1 Jul. 11 at 12:01 PM
$VIR Vir Biotechnology, Inc. VIR shares soared 11.9% in the last trading session to close at $5.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.2% loss over the past four weeks. The sudden rise in the stock price can be attributed to the positive investor mindset regarding the potential of Vir Biotechnology’s only late-stage pipeline candidate, tobevibart. It is being developed in combination with Alnylam’s elebsiran, in a registrational phase III ECLIPSE 1 study for treating chronic hepatitis delta (CHD). VIR is also gearing up to initiate a phase III ECLIPSE 2 study to assess the efficacy and safety of switching to tobevibart and elebsiran in individuals with CHD who have not achieved viral suppression with bulevirtide treatment.
1 · Reply
Dunnieboy1
Dunnieboy1 Jul. 10 at 3:29 PM
$VIR nice bounce the last couple of days.
0 · Reply
BASEflyer
BASEflyer Jul. 9 at 10:42 PM
$VIR huge buys AH
0 · Reply
sittingonagoldmine
sittingonagoldmine Jul. 9 at 7:45 PM
$VIR I am still here, check my Avatar closely... ;-) I remember a recent fireside Chat where Marianne mentioned that the value in Vir is underappreciated. She highlighted that the price for HDV orphan drug will be significant and that VIR has the BEST IN CLASS Hepatitis Delta treatment worldwide. I am glad to see some upside in the share price today, let s hope it will continue. My personal view is that Vir has been significantly undervalued for the last years & that the upside potential at this level is high, even in a situation where VIR won't find a Hep B partner for PH III and commercialization. We have a tremendous HDV and oncology platform! Good luck to all $VIR fellow bulls!!
1 · Reply
BASEflyer
BASEflyer Jul. 9 at 5:41 PM
$VIR she’s alive 😱
0 · Reply
PCIntern
PCIntern Jul. 9 at 3:10 PM
$VIR something perhaps, maybe, possibly, could be “brewing”. Then again…hoo nose??
0 · Reply
Dunnieboy1
Dunnieboy1 Jul. 9 at 1:18 PM
$VIR must say i’m disappointed that Vir haven’t given us a date for the beginning of the Cancer trial Vir 5525 egfr2, we were told on numerous occasions the trial would start in H1 2025 and while we are only 9 days past H1 i believe the company should communicate with shareholders and give us a definite date.
1 · Reply
Dunnieboy1
Dunnieboy1 Jul. 3 at 2:14 PM
$VIR that’s on the gov website for clinical trials, start date 2025-07 no specific date. Intervention / Treatment Drug: VIR-5525 Drug: Pembrolizumab Other Study ID Numbers VIR-5525-V101 U1111-1294-8156 ( Registry Identifier ) (REGISTRY: ICTRP) 2023-508555-39 ( Registry Identifier ) (REGISTRY: CTIS) AMX-525 ( Other Identifier ) (OTHER: Amunix) Study Start (Estimated) 2025-07
1 · Reply
Latest News on VIR
20 stocks you should avoid — no matter how well the market does

Jun 11, 2025, 7:00 AM EDT - 4 weeks ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025, 4:05 PM EDT - 6 weeks ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 20, 2025, 4:05 PM EDT - 7 weeks ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 9, 2025, 6:00 AM EDT - 2 months ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 8, 2025, 3:37 PM EDT - 2 months ago

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:21 PM EDT - 2 months ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 30, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 24, 2025, 9:30 AM EDT - 2 months ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 21, 2025, 7:10 AM EDT - 4 months ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Mar 13, 2025, 8:05 AM EDT - 4 months ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 11:22 PM EST - 4 months ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:05 PM EST - 4 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 4:05 PM EST - 5 months ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 4:05 PM EST - 5 months ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Jan 13, 2025, 6:10 PM EST - 6 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Jan 10, 2025, 2:32 PM EST - 6 months ago

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 9, 2025, 9:00 AM EST - 6 months ago

Vir Biotechnology: A Rocket Off Phase 1 Data

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Jan 8, 2025, 12:28 PM EST - 6 months ago

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Jan 8, 2025, 7:45 AM EST - 6 months ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 9:30 AM EST - 7 months ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Dec 13, 2024, 12:57 PM EST - 7 months ago

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Dec 12, 2024, 4:05 PM EST - 7 months ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 26, 2024, 9:30 AM EST - 8 months ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 9:30 AM EST - 8 months ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Nov 18, 2024, 9:15 PM EST - 8 months ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Nov 18, 2024, 4:05 PM EST - 8 months ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Nov 15, 2024, 11:00 AM EST - 8 months ago

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Nov 5, 2024, 11:29 AM EST - 8 months ago

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 11:12 PM EDT - 9 months ago

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 4:05 PM EDT - 9 months ago

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Oct 17, 2024, 4:30 PM EDT - 9 months ago

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 9 months ago

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Oct 3, 2024, 4:00 PM EDT - 10 months ago

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Sep 10, 2024, 8:05 AM EDT - 11 months ago

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Sep 9, 2024, 4:05 PM EDT - 11 months ago

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 8:05 AM EDT - 11 months ago

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:10 PM EDT - 1 year ago

Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Aug 1, 2024, 4:02 PM EDT - 1 year ago

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Jul 17, 2024, 4:47 PM EDT - 1 year ago

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Jun 26, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

Jun 5, 2024, 5:30 AM EDT - 1 year ago

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

May 29, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

May 23, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

May 22, 2024, 8:05 AM EDT - 1 year ago

Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

Reser's Fine Foods Kicks Off 2024 ‘Good Times Tour'

May 22, 2024, 8:00 AM EDT - 1 year ago

Reser's Fine Foods Kicks Off 2024 ‘Good Times Tour'

SAIC

BASEflyer
BASEflyer Jul. 11 at 2:56 PM
$VIR lol down almost 5% with 250k volume 🤣🤣🤣
0 · Reply
JarvisFlow
JarvisFlow Jul. 11 at 1:05 PM
Raymond James has updated their rating for Vir Biotechnology ( $VIR ) to Outperform with a price target of 12.
1 · Reply
Dunnieboy1
Dunnieboy1 Jul. 11 at 12:01 PM
$VIR Vir Biotechnology, Inc. VIR shares soared 11.9% in the last trading session to close at $5.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.2% loss over the past four weeks. The sudden rise in the stock price can be attributed to the positive investor mindset regarding the potential of Vir Biotechnology’s only late-stage pipeline candidate, tobevibart. It is being developed in combination with Alnylam’s elebsiran, in a registrational phase III ECLIPSE 1 study for treating chronic hepatitis delta (CHD). VIR is also gearing up to initiate a phase III ECLIPSE 2 study to assess the efficacy and safety of switching to tobevibart and elebsiran in individuals with CHD who have not achieved viral suppression with bulevirtide treatment.
1 · Reply
Dunnieboy1
Dunnieboy1 Jul. 10 at 3:29 PM
$VIR nice bounce the last couple of days.
0 · Reply
BASEflyer
BASEflyer Jul. 9 at 10:42 PM
$VIR huge buys AH
0 · Reply
sittingonagoldmine
sittingonagoldmine Jul. 9 at 7:45 PM
$VIR I am still here, check my Avatar closely... ;-) I remember a recent fireside Chat where Marianne mentioned that the value in Vir is underappreciated. She highlighted that the price for HDV orphan drug will be significant and that VIR has the BEST IN CLASS Hepatitis Delta treatment worldwide. I am glad to see some upside in the share price today, let s hope it will continue. My personal view is that Vir has been significantly undervalued for the last years & that the upside potential at this level is high, even in a situation where VIR won't find a Hep B partner for PH III and commercialization. We have a tremendous HDV and oncology platform! Good luck to all $VIR fellow bulls!!
1 · Reply
BASEflyer
BASEflyer Jul. 9 at 5:41 PM
$VIR she’s alive 😱
0 · Reply
PCIntern
PCIntern Jul. 9 at 3:10 PM
$VIR something perhaps, maybe, possibly, could be “brewing”. Then again…hoo nose??
0 · Reply
Dunnieboy1
Dunnieboy1 Jul. 9 at 1:18 PM
$VIR must say i’m disappointed that Vir haven’t given us a date for the beginning of the Cancer trial Vir 5525 egfr2, we were told on numerous occasions the trial would start in H1 2025 and while we are only 9 days past H1 i believe the company should communicate with shareholders and give us a definite date.
1 · Reply
Dunnieboy1
Dunnieboy1 Jul. 3 at 2:14 PM
$VIR that’s on the gov website for clinical trials, start date 2025-07 no specific date. Intervention / Treatment Drug: VIR-5525 Drug: Pembrolizumab Other Study ID Numbers VIR-5525-V101 U1111-1294-8156 ( Registry Identifier ) (REGISTRY: ICTRP) 2023-508555-39 ( Registry Identifier ) (REGISTRY: CTIS) AMX-525 ( Other Identifier ) (OTHER: Amunix) Study Start (Estimated) 2025-07
1 · Reply
Dunnieboy1
Dunnieboy1 Jul. 2 at 9:23 PM
$VIR Vicki Sato Chairman/person has disposed of another 22,000 shares. report says she still holds 1.3m shares.
1 · Reply
Estimize
Estimize Jul. 2 at 9:00 PM
Wall St is expecting -0.74 EPS for $VIR Q2 [Reporting 07/31 AMC] http://www.estimize.com/intro/vir?chart=historical&metric_name=eps&utm_con
0 · Reply
Dunnieboy1
Dunnieboy1 Jul. 1 at 9:08 PM
$VIR Vicki Sato Chairman has sold 66,000 shares for over $330,000, the shares were gifted to her pre-ipo, she still has over 138,000 shares.
1 · Reply
Dunnieboy1
Dunnieboy1 Jun. 30 at 8:09 PM
$VIR 🤷
1 · Reply
Dunnieboy1
Dunnieboy1 Jun. 29 at 11:17 PM
$VIR Marianne De Backer the CEO told us we would start a third cancer trial Vir-5525 in H1 2025, today is the last day of H1 2025, bring it on Vir!
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 27 at 6:15 PM
$VIR For investors with an eye on the healthcare sector, Vir Biotechnology, Inc. (NASDAQ: VIR) presents a compelling opportunity. Operating within the biotechnology industry, Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing therapies to treat and prevent serious infectious diseases. Based in San Francisco, the company is at the forefront of innovation, leveraging strategic partnerships with industry giants like GlaxoSmithKline and Sanofi. Despite its promising clinical pipeline, Vir Biotechnology is navigating a challenging financial landscape. The company currently boasts a market capitalization of approximately $720.22 million, with its stock priced at $5.21 per share. However, it’s the potential growth trajectory that has captured investor attention, with analyst ratings projecting a notable upside of 243.09%.
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 24 at 12:54 PM
$VIR bank of America maintain a hold rating on Vir, price target $12
0 · Reply
Dunnieboy1
Dunnieboy1 Jun. 23 at 9:58 PM
$VIR 5 more trading days left in H1 2025, we were told the 3rd Cancer trial would begin in H1 so hopefully the share price reacts well to the new trial starting, it should do as it shows the company are satisfied with the data from the other 2 clinical trials otherwise they would commit the funding to a 3rd trial.
0 · Reply
Abovezero0000
Abovezero0000 Jun. 17 at 1:07 AM
$VIR Very likely that the news will be dropped on a monday, only 2 more mondays left in the month (23rd & 31st). Im betting on the 23rd, I think mary ann said something like ”towards the end of the month” so very unlikey they would drop it on the very last day of the month, but still possible. Keep in mind under normal conditions their market cap is off by $150M-$200M off their current cash/cash equivalents. So when next quarter is announced with a cash pile of $865M the market cap should start to fall to high 600’s to low 700’s if theres no major news. But with mary ann saying that they’re in ”Deep discussions” with potential partners recently, anything can happen. Nobody really knows when that news will pop and the extent of how beneficial it will be for us, I would bet that by mid 2026 or sooner is when they should announce a major partnership with the Hepatits D. Obviously they shouldn't want to release crucial data mid 2027 at the same time that they run out cash…
2 · Reply
Dunnieboy1
Dunnieboy1 Jun. 14 at 11:57 AM
$VIR are launching a third phase 1 cancer trial this month, so the trial is going to be announced in the next 10 trading days(mkt is closed June 19). I would expect a positive response for the sp on this news as it gives further endorsement to our cancer therapies & to the pro-xten platform we have licensed from Sanofi.
1 · Reply
sittingonagoldmine
sittingonagoldmine Jun. 13 at 9:42 PM
$VIR How can this guy have so many followers posting information which is not right about VIR? He is not even double checking information here! And who is giving him LIKES for misstated information ? Typically, everyone just posting AI driven info and does not double check.... Very bad attitude and wrong!
0 · Reply
jbrown645
jbrown645 Jun. 13 at 6:45 PM
$VIR
2 · Reply